// App-Quantinova.ai

P169 : Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis

Researchers

Presenter

  • Dennis McGonagle

Principal Investigators

  • Arthur Kavanaugh

  • Iain McInnes

  • Lars-Erik Kristensen

  • Joseph F Merola

  • Bruce E Strober

  • Jeffrey R Lisse

  • Jennifer Pustizzi

  • Christophe Sapin

  • Rebecca Bolce

  • Christopher Ritchlin

Medical Centers

  • Department of Experimental Pathology, Yale University, New Haven, CT

  • Department of Medicine, Division of Rheumatology, and Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

  • Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA

  • Department of Rheumatology, Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom

  • Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY

  • Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg & Frederiksberg Hospital, Frederiksberg, Denmark

  • Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom

Locations

  • United States

  • Denmark

  • United Kingdom

Companies

  • EMB Statistical Solu

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved